Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial microplasmin for acute vertebrobasilar artery occlusion
NL-OMON31313Phase 2Withdrawn
- Sponsor
- Oxurion
- Start
- Jun 2007
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ocriplasmin in ischemic stroke and vertebrobasilar artery occlusion (VBAO), sponsored by Oxurion. Primary endpoints: Basilar artery recanalization, Intracranial hemorrhage and 8 more. Planned start Jun 2007; status: withdrawn.
02
Drugs
ocriplasmin
03
Conditions
ischemic strokevertebrobasilar artery occlusion (VBAO)
Beyond the preview
Go deeper on NL-OMON31313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31313.